double-digit growth growth driver freestyl libr mitraclip alin
maintain buy rate abbott upgrad tp
provid upsid potenti
deriv estim base forward
price-to-earnings multipl ep
estim price/sal
expect sales/shar
respect estim top-lin revenu grow
base key growth driver
freestyl libr mitraclip alin
estim base follow factor revenu
growth fda approv variou product strong segment
abbott deliv strong perform quarter due
acceler sale growth double-digit growth ep abbott
deliv strong perform total revenu
increas compar
monitor system achiev world-wide sale
quarter increas report basi
organ basi versu prior year freestyl libr
reimburs peopl privat pharmaci
world-wide sale mitraclip quarter
increas report basi organ
basi versu prior year includ growth
compani nametickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
abbott announc fda approv next-gener
mitraclip devic offer enhanc size
offer doctor option
juli abbott receiv fda approv alinity-
diagnost system latest technolog screen
protect blood plasma suppli alinity-
design provid faster effici result within
system maintain highest level accuraci
establish pharmaceut sale decreas
decreas
decreas due unfavor
effect foreign exchang increas
increas accord organ basi
world-wide diagnost revenu increas
report basi increas organ basi
includ unfavor effect
world-wide medic devic sale increas
report basi organ basi
sale increas increas
growth led double-digit growth
electrophysiolog heart failur structur heart
compani expect organ sale growth
current price-to-earnings trade
due increas stock price
price-to-earnings
averag price-to-earnings expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend ex-dividend last split factor new per last split date jan inform abbott laboratori septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total revenu gross profit research develop sale gener total oper expens oper incom interest expens currenc exchang gain non oper incom earn incom tax expens earn continu oper earn discontinu oper net incom ep basic ep dilut weight averag share outstand basic dilut estim annual actual annual actual quarterli abbott laboratori septemb
balanc sheet item short term invest total st account receiv total receiv inventori prepaid expens current asset total current asset gross properti plant accumul depreci net properti plant equip long-term invest tangibl defer tax asset long-term asset total asset equiti liabil account payabl accru expens short-term current portion lt debt current incom tax payabl current liabil total current liabil long-term pension post-retir benefit def tax liabil non-curr liabil total liabil common stock retain earn treasuri stock comprehens incom total common minor interest total equiti total liabil equiti actual annual actual quarterli septemb
net oper activ decreas due primarili time
pension contribut increas invest work capit higher cash
tax paid partial off-set higher oper earn also includ cash tax
net use invest activ increas compar
net use financ activ decreas compar
incom depreci amort goodwil intang depreci amort total loss sale asset loss sale invest stock-bas compens oper activ chang account receiv chang inventori chang account payabl chang net oper asset oper invest activ capit expenditur acquisit divestitur invest market equiti secur invest activit invest financ activ short term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid issuanc common stock repurchas common stock common prefer stock dividend financ chang equival foreign exchang rate adjust net chang actual annual actual quarterli septemb
abbott deliv acceler sustain growth driven strong
perform key product freestyl libr alin mitraclip
compar
total revenu increas compar
increas accord organ basi
increas impact chang foreign exchang rate
increas
compar
total us revenu increas compar
revenu increas
compar increas affect
rel stronger us dollar
cog decreas compar
amort intang asset decreas
compar gross profit margin increas
compar
 expens increas compar
increas off-set effect favour foreign exchang
decreas cost relat acquir asset compar
sg expens decreas compar
oper earn increas compar
interest expens decreas
compar
incom net decreas compar
decreas due record unreal gain
invest result observ price chang
similar invest issuer
tax earn continu oper increas
compar net earn increas
compar
compar
compar
basic ep increas compar
dilut ep increas compar
total revenu increas report basi organ basi
compar increas
accord organ basi total us revenu increas
compar
revenu increas
compar increas affect rel
cog increas compar
amort intang asset decreas
compar
gross profit margin increas compar
increas due favor comparison versu
lower intang amort expens restructur cost
 expens increas compar
increas due asset acquir valu
also increas expens relat variou busi includ
cardiovascular neuromodul increas partial off-set
favor affect foreign exchang
oper earn increas compar
interest expens decreas
compar decreas due
reduct interest expens result favor impact euro
debt refinanc septemb well repay debt
incom net decreas compar
decreas due impair certain equiti
invest partial off-set higher incom relat
non-servic cost compon net period benefit cost associ
pension post-retir benefit plan
compar
tax earn continu oper decreas
compar decreas due
reduct transit tax liabil result issuanc final
transit tax regul us depart treasuri
adjust decreas cumul net tax expens relat tcja
net earn increas compar
basic ep increas
compar dilut ep increas
compar
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic segment revenu
total revenu follow
establish pharmaceut sale decreas
compar decreas
compar decreas
due unfavor effect foreign exchang increas
increas accord organ
emerg market includ india brazil russia china along
sever addit emerg countri repres attract
long-term growth opportun abbott brand gener product
sale geographi decreas report
basi decreas includ
unfavor effect foreign exchang increas
organ basi led strong growth across sever countri includ india
china
sale decreas report basi
decreas includ unfavor
effect foreign exchang increas organ basi
sale growth neg impact recent
discontinu non-cor low-margin suppli agreement
world-wide revenu nutrit product increas
report basi compar
increas compar
organ basi sale increas
increas
decreas
decreas
increas
increas
total nutrit product revenu increas
decreas total
intern revenu increas
increas
world-wide pediatr nutrit revenu remain flat
compar increas
includ unfavor effect foreign exchang
increas organ basi
total pediatr nutrit revenu increas
increas
intern pediatr nutrit sale decreas report
basi increas organ basi
increas
sale perform quarter led broad-bas growth
across sever brand includ above-market growth sever
countri latin america asia
world-wide adult nutrit revenu increas report
basi organ basi increas
report basi organ basi
increas led strong growth ensur abbott
market-lead complet balanc nutrit brand glucerna
total revenu decreas
decreas intern adult nutrit
sale increas increas
world-wide revenu
remain flat
increas
increas
increas
world-wide diagnost revenu increas report basi
increas organ basi
increas report basi increas organ basi
includ unfavor effect foreign
diagnost product revenu increas
increas total
intern revenu decreas
decreas
laboratori diagnost revenu increas report
basi increas organ basi
increas report basi increas organ
basi
sale perform quarter led above-market growth
intern abbott achiev continu strong adopt
alin famili innov highli differenti diagnost
instrument juli abbott receiv us fda approv alinity-
diagnost system sever test assay design provid faster
effici result within smaller space maintain
highest level accuraci
total revenu increas
increas total intern revenu
increas increas
revenu increas
increas
increas
increas
decreas
decreas
world-wide point
increas
increas
decreas
decreas
world-wide molecular diagnost revenu decreas
decreas includ
unfavor effect foreign exchang decreas
organ basi sale growth quarter neg impact
non-government organ ngo purchas pattern africa
total revenu decreas
increas total intern revenu
declin decreas
point diagnost
world-wide point diagnost revenu increas
increas
includ unfavor effect foreign exchang increas
organ basi sale growth led compani
lead i-stat handheld system us intern
total revenu increas
increas total intern
revenu increas decreas
world-wide rapid diagnost sale decreas
includ unfavor effect foreign exchang
increas organ basi sale decreas
total revenu increas
increas total intern revenu
declin decreas
world-wide medic devic sale increas report basi
increas
organ basi sale increas increas
growth led double-digit growth
electrophysiolog heart failur structur heart diabet
medic devic revenu increas
increas total intern
revenu increas increas
cardiovascular neuromodul
cardiovascular neuromodul revenu increas
report basi increas
organ basi revenu increas
increas
total cardiovascular neuromodul revenu
increas increas
total intern revenu decreas
decreas
electrophysiolog revenu increas
increas revenu growth
led strong perform cardiac diagnost ablat cathet
use help physician accur effect treat atrial
fibril form regular heartbeat
increas
revenu increas
increas
revenu increas
increas
cardiovascular neuromodul
structur heart revenu increas
increas total revenu us increas
increas
revenu increas
increas
growth structur heart led mitraclip abbott market-
lead devic minim invas treatment mitral
regurgit abbott receiv us fda approv new expand
indic mitraclip treat clinic signific secondari mitral
regurgit result underli heart failur
new indic significantli expand number peopl
treat mitraclip abbott announc us fda approv next-
gener mitraclip devic mitraclip offer expand
rang clip size altern leaflet grasp featur facilit
procedur assess real time offer doctor option
treat mitral valv diseas
increas
increas
heart failur revenu increas
increas growth revenu
driven market adopt abbott heartmat left ventricular assist
devic follow us fda approv destin therapi late
total us revenu increas
increas revenu
increas increas
cardiovascular neuromodul
revenu declin
decreas
neuromodul revenu declin
decreas vascular revenu declin
declin
rhythm manag revenu declin
declin
increas
report basi
organ basi
diabet sale increas report basi
organ basi increas
sale growth led freestyl libr
abbott revolutionari continu glucos monitor system
world-wide sale increas report basi
organ basi
total sale increas
increas sale
increas increas
organ sale growth
abbott project organ sale growth dilut ep
abbott forecast net specifi item
per share
expens charg associ cost reduct initi
abbott expect ep abbott
forecast specifi item per share primarili relat
intang amort acquisition-rel expens cost reduct
initi expens
continu oper would
abbott expect ep
acceler
quarter driven strong
perform across
abbott sale growth acceler quarter driven strong
perform across portfolio total revenu increas
increas gross profit
margin increas increas
increas due favor comparison versu lower intang
amort expens restructur cost
establish pharmaceut sale decreas
decreas decreas due
unfavor effect foreign exchang increas
increas accord organ basi
laboratori diagnost revenu increas
increas sale perform
quarter led above-market growth intern abbott
achiev continu strong adopt alin famili innov
abbott partner poli ifornia cybersecur institut challeng
hacker cybersecur research juli abbott receiv fda
approv alinity- diagnost system latest technolog
screen protect blood plasma suppli alinity-
design provid faster effici result within smaller space
versu commerci avail competit system maintain
highest level accuraci
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin ttm basi compar
oper margin increas ttm basi compar
y/i revenu growth ttm basi compar
net margin increas ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori septemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale abbott laboratori septemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset abbott laboratori septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott laboratori septemb
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free septemb
current price-to-earnings trade due increas stock price
price-to-earnings averag price-to-earnings expect forward
price-to-earnings multipl
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global wellington manag compani massachusett servic northern trust corpor fmr geod capit manag llc top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani vanguard growth fund america amcap spdr etf vanguard institut fund-institut vanguard specialized-health vanguard specialized-dividend appreci fidel fund abbott laboratori septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
consensu view analyst trend stock
forecast
compar
abbott forward price-to-earnings
compar
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last daysn/an/an/an/aup last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr abbott laboratori septemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price volatil quarter dip june later surg
result
stock gave return past
stock price movement show upward trend last one year surg
stock gave return last one year rang stock
stock price movement shown upward trend past surg juli
stock gave return past
abbott deliv strong perform quarter due growth driver includ freestyl libr
mitraclip alin achiev except growth maintain buy rate abbott
tp estim base abt perform quarter strong
advanc pipelin
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
